Back to News
NewsJobs

AI-Driven Cancer Vaccine Completes Third Phase of Trials

Merck and Moderna report success in phase three trials for their personalized mRNA melanoma vaccine, achieving key endpoints.

Mercation Admin
August 20, 2026 2 min read
AI-Driven Cancer Vaccine Completes Third Phase of Trials

On August 19, pharmaceutical leader Merck and biotech firm Moderna announced a significant advancement in their personalized mRNA vaccine for melanoma, which has successfully achieved its primary and a key secondary endpoint in the third phase of clinical trials.

The experimental treatment, known as intismeran autogene (V940 or mRNA-4157), was administered alongside Merck's established anti-cancer drug, Keytruda.

Clinical Trial Highlights

The INTerpath-001 study involved 1,137 patients diagnosed with stages IIB-IV melanoma, all of whom had undergone complete tumor removal. Participants were split into two groups: one received the combination of intismeran autogene and Keytruda, while the control group received Keytruda alone.

Results indicated a statistically significant enhancement in both recurrence-free survival and distant metastasis-free survival for those receiving the combination therapy. This marks a pivotal achievement as the first positive outcome in phase three for personalized neoantigen therapies and mRNA-based cancer treatments.

While specific efficacy metrics remain undisclosed, researchers plan to present detailed findings at an international medical conference. The ongoing study will continue to evaluate overall survival and additional parameters, with no new safety concerns reported compared to earlier trials.

In earlier phases, the combination treatment outperformed Keytruda alone, showing a 49% reduction in the risk of recurrence or death and a 59% decrease in the risk of distant metastasis or death over five years.

Innovations in Vaccine Development

Intismeran autogene is uniquely designed for each patient, diverging from traditional vaccines. The development process begins with sequencing tumor and blood samples, followed by analysis using Moderna’s algorithms to identify up to 34 neoantigens that can trigger an immune response.

Using these insights, a personalized mRNA vaccine is created to train the immune system to recognize and attack cancer cells. Moderna leverages integrated AI tools not only to analyze genetic data but also to optimize manufacturing logistics, ensuring efficient production of these individualized vaccines.

Keytruda, on the other hand, enhances the immune response by blocking tumor cells' mechanisms that suppress it. Together, these therapies work synergistically to bolster the immune system’s ability to target and eliminate cancer cells.

Market Reaction and Future Plans

Following the trial results announcement, Moderna’s stock skyrocketed by approximately 131%, reaching $163, marking the largest single-day increase in the company's history. However, the stock has since seen a nearly 15% decline.

This surge had significant implications for traders who had shorted Moderna's stock, leading to unrealized losses of around $4.8 billion, as reported by analytics platform ORTEX. Prior to this event, 13.5% of the company’s shares were sold short.

Merck and Moderna are set to present their findings to regulatory bodies and discuss potential approval for the intismeran autogene and Keytruda combination. The therapy is still experimental and awaits official approval for use.

Additionally, the companies are investigating the application of intismeran autogene for various other cancers, including lung, bladder, and kidney tumors. In related advancements, a Google AI model recently identified a drug combination to make "cold" tumors detectable by the immune system, a hypothesis validated through laboratory tests. A neural network from Redmod has also shown the ability to identify pancreatic cancer significantly earlier than traditional diagnostic methods.